Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Clinical trial NCT04053322 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04053322
Sponsor: UNICANCER
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

Start date: 2019-08-26
Primary completion: 2023-11-15
Enrollment: 172

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.